Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Mark Brosius Sells 489 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Mark Brosius sold 489 shares of Intuitive Surgical stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $533.18, for a total transaction of $260,725.02. Following the sale, the senior vice president now owns 2,091 shares in the company, valued at approximately $1,114,879.38. This represents a 18.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mark Brosius also recently made the following trade(s):

• On Wednesday, March 5th, Mark Brosius sold 492 shares of Intuitive Surgical stock. The stock was sold at an average price of $554.17, for a total transaction of $272,651.64.
• On Monday, March 3rd, Mark Brosius sold 492 shares of Intuitive Surgical stock. The stock was sold at an average price of $573.78, for a total transaction of $282,299.76.

Intuitive Surgical Trading Down 3.8 %

Shares of ISRG stock opened at $518.26 on Monday. The firm has a market capitalization of $184.59 billion, a PE ratio of 80.85, a price-to-earnings-growth ratio of 5.85 and a beta of 1.43. The firm has a fifty day simple moving average of $571.36 and a two-hundred day simple moving average of $531.85. Intuitive Surgical, Inc. has a 12 month low of $364.17 and a 12 month high of $616.00.

Institutional Trading of Intuitive Surgical

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. IronOak Wealth LLC. bought a new stake in shares of Intuitive Surgical in the 4th quarter worth $1,595,000. TFR Capital LLC. bought a new stake in shares of Intuitive Surgical in the 4th quarter worth $3,252,000. Siemens Fonds Invest GmbH grew its stake in shares of Intuitive Surgical by 795.2% in the 4th quarter. Siemens Fonds Invest GmbH now owns 143,818 shares of the medical equipment provider’s stock worth $75,067,000 after acquiring an additional 127,753 shares in the last quarter. BridgePort Financial Solutions LLC bought a new stake in shares of Intuitive Surgical in the 4th quarter worth $330,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Intuitive Surgical in the 4th quarter worth $167,943,000. Institutional investors own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. BTIG Research boosted their price target on shares of Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Truist Financial boosted their price target on shares of Intuitive Surgical from $640.00 to $666.00 and gave the stock a “buy” rating in a research report on Friday, January 24th. CICC Research assumed coverage on shares of Intuitive Surgical in a research report on Monday, January 27th. They issued a “neutral” rating and a $550.00 price target on the stock. Leerink Partners boosted their price target on shares of Intuitive Surgical from $490.00 to $548.00 in a research report on Monday, January 27th. Finally, UBS Group boosted their price target on shares of Intuitive Surgical from $500.00 to $560.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $613.10.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.